Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 01, 2018 07:00 ET | Source: Antares Pharma, Inc.

Antares Receives FDA Approval of Xyosted™ (Testosterone Enanthate) Injection for Testosterone Replacement Therapy in Adult Males

A Novel Subcutaneous Auto Injector Product Approved For Once-Weekly At-Home Therapy EWING, N.J., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced the approval...
September 25, 2018 07:00 ET | Source: Antares Pharma, Inc.

Antares Pharma to Present at the Ladenburg Thalmann 2018 Healthcare Conference

EWING, N.J., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Ladenburg...
August 30, 2018 07:00 ET | Source: Antares Pharma, Inc.

Antares Pharma to Present at the Rodman & Renshaw 20th Annual Global Investment Conference

EWING, N.J., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Rodman &...
August 16, 2018 16:54 ET | Source: Antares Pharma, Inc.

Antares Pharma Announces FDA Approval of Generic EpiPen Utilizing VIBEX Auto Injector

EWING, N.J., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) today announced that the U.S. Food and Drug Administration (FDA) has approved Teva Pharmaceutical...
August 07, 2018 07:00 ET | Source: Antares Pharma, Inc.

Antares Pharma Reports Second Quarter 2018 Operating and Financial Results

EWING, N.J., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the Company) today reported operating and financial results for the second quarter ended June 30, 2018. The...
August 06, 2018 16:30 ET | Source: Antares Pharma, Inc.

Antares Pharma Appoints Dr. James Tursi Executive Vice President, Head of Research & Development, Chief Medical Officer

EWING, N.J., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of James P. Tursi M.D. to the position of Executive Vice President, Head of...
August 06, 2018 07:00 ET | Source: Antares Pharma, Inc.

Antares Pharma Enters Into Development Agreement With Pfizer Inc.

EWING, N.J., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) today announced that it has entered into an agreement with Pfizer Inc. (“Pfizer”) to develop a...
July 31, 2018 07:00 ET | Source: Antares Pharma, Inc.

Antares Pharma to Report Second Quarter 2018 Financial and Operating Results

EWING, N.J., July 31, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its second quarter 2018 financial results and recent operating progress before the...
May 30, 2018 07:00 ET | Source: Antares Pharma, Inc.

Antares Pharma Announces Receipt of Third Installment From Sale of ZOMAJET™ Needle-Free Delivery System

EWING, N.J., May 30, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (“Antares”) (“The Company”) today announced that it has received $4.75 million from Ferring Pharmaceuticals...
May 29, 2018 07:00 ET | Source: Antares Pharma, Inc.

Antares Pharma to Present at the Jefferies 2018 Healthcare Conference

EWING, N.J., May 29, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Jefferies 2018...